Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Atorvastatin (Primary)
- Indications Atherosclerosis; Dyslipidaemias
- Focus Therapeutic Use
- 07 Oct 2014 Biomarkers information updated
- 19 Sep 2013 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 19 Oct 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.